Stop by and read some of our latest articles and updates in the world of Mental Health & Stability. Browse previous posts on the left, or click the search bar to the right to find a specific topic.

Archive for ◊ February, 2013 ◊

• Friday, February 22nd, 2013

Alcoholism is a progressive disease characterized by four primary attributes which include preoccupation (increase desire to drink), physical dependence, lack of self-restraint, and development of tolerance.
Over the years research has improved our general understanding of the devastating potential this disease presents for alcohol abusers. By analyzing current alcoholism statistics we see the effects of alcohol on behaviors and society.
• Alcohol dependence and abuse cost the U.S taxpayers approximately $276 billion in 2005.
• Alcoholism improves a drinker’s odds of developing cancer of the throat, larynx, liver, colon, kidneys, rectum and esophagus. It is believe to contribute to immune system disorders, brain damage, harming the unborn and cirrhosis of the liver.
• 43% of U.S. citizens are related to someone who is presently alcoholic.
• 13.8 million U.S. adults have personal issues with alcohol, while 8.1 million of that number, officially suffer alcoholism.
• It takes about 15 years for an adult to become a full-fledge alcoholic, but the process is sped up considerably in teens and young adults. In contrast with those who drink in moderation, people who abuse alcohol are estimated to spend from 1.5% to 18.7% of their total income on alcohol and alcohol related items. The large fluctuation is largely based on age and sex.
• One half million U.S. children aged nine to 12 are addicted to alcohol.
• Non-alcoholic members of alcoholic’s families use 10 times as much sick leave as families where alcohol is not a problem. 80% of these family members report their ability to perform work is significantly impaired as a result of living with an alcoholic abuser.
• Alcoholics spend 4 times the amount of time in the hospital as non-drinkers, mostly from drinking related injuries.
With the use of a good nutritional supplement, as those contained in the QuietMinds formula, augmented with other inexpensive vitamins, minerals and amino acids that can be purchased at the average vitamin outlet, people can stop alcohol cravings and restore themselves to good health.
Obviously, alcohol is a liquid sugar which is evident by looking at its chemical formula. Dr. Abram Hoffer, MD, PhD determined many years ago that biochemical individuality and sugar cravings contributed to alcoholism, especially if his patients had low blood sugar or problems metabolizing alcohol. As a biochemist, Hoffer reasoned that niacin (vitamin B3) could restore mental health, even after repeated episodes of drinking. He researched vitamin therapy for decades, found the practice safe and effective, subsequently helping thousands of patients recover and live well.
Realizing that most physicians don’t test for biochemical disorders, monitor nutrition and prescribe vitamins, Hoffer wrote a series of books for patients, families and caregivers in which he introduced biochemistry, summarized research and shared scientific and medical information about orthomolecular medicine. Prior to that Abram Hoffer had published his research in scientific and medical journals only to become disappointed and perplexed when the American Psychiatry Association refused to accept his research or conduct their own double-blind placebo-controlled study to confirm or disprove his findings.
Sometime around 1960 while doing his research, Abram Hoffer met and became friends with the co-founder of Alcoholic Anonymous, Bill W. Dr. Hoffer maintained his personal interest in alcoholism and had come to the attention of Bill W. who learned of Hoffer’s use of mega vitamin therapy for treating of alcoholics and “became very enthusiastic about it because niacin gave these unfortunate patients immense relief from their chronic depression and other physical and mental complaints.”
Hoffer described to Bill W. the positive results that he and his research partner, Dr. Humphrey Osmund, were experiencing with the treatment of schizophrenic patients, some of whom were also alcoholic. He recounts in his paper “Vitamin B-3: Niacin and its Amide” about which Bill W. was very curious concerning the vitamin and niacin research “and began to take niacin 3 g daily.” Within six months he was convinced that orthomolecular treatment for alcoholics was going to be helpful to alcoholics and gave niacin to 30 of his close friends in AA and persuaded them to try it. Twenty of them were free of anxiety, tension and depression within two months. He wanted to persuade members of AA, especially the doctors in AA, that orthomolecular supplementation would be a useful addition to treatment. “Bill became unpopular with the members of the board of AA International. The medical members who had been appointed by Bill, felt that he had no business messing about with treatment using vitamins.” They “knew” that vitamin therapy could not be therapeutic as Bill had found itl Hoffer concluded, “For this reason Bill provided information to the medical members of AA outside of the National Board, distributing three of his amazing pamphlets at his own expense. They are now not readily available.”
Hoffer findings followed the conclusions from scientific examinations of Nobel Prize winner Roger Williams, PhD, an American biochemist who named folic acid and discovered pantothenic acid. Williams was researching vitamins in the 1940s and observed that lab rats vary in their tolerance for alcohol. By experimenting with vitamins he recommended that vitamins could and should be used for treating alcoholism and developed the concept of biochemical individuality. Subsequently, in 1959 he released a stellar paper, Alcoholism – The Nutritional Approach. Since that time many other research documents have been released on the subject of treating alcoholism with orthomolecular nutrition, including other papers by Abram Hoffer, Humphrey Osmond and others. The most recent definitive work was released in 2009, The Vitamin Cure for Alcoholism. This concise 134 page book is authored by Andrew Saul, PhD, and Abram Hoffer shortly before his death.
What should the alcoholic do to stop drinking and return his or her body to a normally functioning one?
1. Commence QuietMinds Nutritional Supplements starting at the recommended beginning levels and graduate up to the eight capsules, four times per day, for a total of 32 capsules daily.
2. Take vitamin C to saturation, (on the order of 10,000 to 20,000 mg per day). The high doses of vitamin C chemically neutralize the toxic breakdown products of alcohol metabolism. Vitamin C also increases the liver’s ability to reverse the fatty acid build-up that are common in alcoholics.
Note: To titrate to saturation, take 1,000 mg. of vitamin C every hour. When saturation is reached, there will be a single episode of diarrhea; then reduce the dosage to 1000 mg. every four hours.
3. Augment QuietMinds formula with an additional B50 complex tablet/capsule, which contains at least 50mg of each of the B-vitamins, 6 times per day.
4. Augment the QuietMinds formula with three tablespoons of Lecithin, daily.
Note: This provides additional inositol and choline. Their functions are related to the B- complex above. Also, lecithin mobilizes fats out of the liver.
5. Augment QuietMinds Nutritional Supplements with 3000 mg of L-Glutamine, daily.
Note: L-Glutamine is an amino acid that decreases physiological cravings for alcohol. It is one of two primary energy providers that burn glycogen to provide fuel to the brain, while stimulating many neuro-functions. L-Glutamine is naturally produced in the liver and the kidneys. Alcohol harms the kidney and the liver, so supplementation is vital. Concurrently L-Glutamine reduces alcohol and sugar cravings.

After arriving at the recommended QuietMinds loading dose, faithfully continue the 32 capsule regimen for at least 16 weeks, or until stability is established and any craving for alcohol has thoroughly been eliminated.

Contact QuietMinds at: 1-855-KASSIDI (855-527-7434) or (720)-234-7739, for a specialist to recommend telephone counselors and therapists who are qualified to direct your recovery.

• Friday, February 22nd, 2013

It will come as no surprise to anyone following issues in the treatment of mental illness

and central nervous system disorders that the medical psychiatric community and the

pharmaceutical industry seem to be rift with charges of conflicts of interest.

As an example, over the last year, numerous reliable North American news sources have

questioned why nearly 7 out of 10 of the committee members responsible for creating the

DSM-5, (the Fifth Edition of the Diagnostic and Statistical Manual of Mental Illness),

have acknowledged  financial ties to the powerful international pharmaceutical  community.

The DSM is essentially the Bible for researchers, clinicians, psychiatric drug regulation

agencies. health insurance companies, as well as policy makers and pharmaceutical

companies.

Obviously these facts seem to confirm, what has been long suspected by many, which is–

the medical psychiatric and the pharmaceutical industry are riddled with conflicts of interest

and financial relationships —at the expense of the patients themselves. As example, in the

new DSM-5, for which these people are responsible, the definition of depression has been

expanded to include bereavement-a change which, The Washington Post suggests, could

give drug companies a potential $10 billion dollar increase in antidepressant sales,

 Peter Whoriskey, Washington Post , December 26. 2012.

While no evidence has come to light showing that committee members broadened the diagnosis to aid the drug companies, the process of developing the handbook was fraught with financial links to the industry:

■ Eight of 11 members of the APA committee that spearheaded the change reported financial connections to pharmaceutical companies — either receiving speaking fees, consultant pay, research grants or holding stock, according to the disclosures filed with the association. Six of the 11 panelists reported financial ties during the time that the committee met, and two more reported financial ties in the five years leading up to the committee assignment, according to APA records.

■ A key adviser to the committee — he wrote the scientific justification for the change — was the lead author of the 2001 study on Wellbutrin, sponsored by GlaxoWellcome, showing that its antidepressant Wellbutrin could be used to treat bereavement.

■ In 2010, another APA panel developed guidelines on how to treat patients once they have been diagnosed with major depression, including advice on medication. Six of the seven panelists had received consultant pay, lecture fees or research support from pharmaceutical companies, according to their disclosures. The association also appointed an oversight panel that declared that the recommendations had been free of bias, but most of the members of the “independent review panel” had previous financial ties to the industry.

In an interview, APA chief executive James H. Scully Jr. noted that in preparing the new handbook the organization had taken steps to reduce conflicts of interest. Two years before the Institute of Medicine published its restrictions, the APA required that panel members regularly file disclosures and placed limits on their financial connections to drug companies.

Each work group member was allowed to receive as much as $10,000 a year in income from pharmaceutical companies and hold as much as $50,000 in stock. Members could also receive unlimited amounts of money from pharmaceutical companies to conduct research.                                                                       (Whoriskey, 2012) .

The DSM-5 has been developed by an American Psychological Association appointed task force and various panels consisting of experts in diverse fields of psychiatry. But many of these experts serve, or have served, as paid spokespeople or scientific advisors for drug companies, or conduct pharmaceutical industry-funded research. Some of the most conflicted panels are those for which drugs represent the first line of treatment, with two-thirds of the mood disorders panel, 83 percent of the psychotic disorders panel and 100 percent of the sleep disorders panel disclosing “ties to the pharmaceutical companies that manufacture the medications used to treat these disorders or to companies that service the pharmaceutical industry,” according to the study.

“We’re not trying to say there’s some Machiavellian plot to bias the psychiatric taxonomy,” said Lisa Cosgrove, professor of psychology at the University of Massachusetts, and who is also a research fellow at Harvard’s Edmond J. Safra Center for Ethics. “But transparency alone cannot mitigate unintentional bias and the appearance of bias, which impact scientific integrity and public trust.”

“We’re not opposed to the proper use of psychiatric drugs when there’s a real diagnosis and when a child or an adult needs pharmacological intervention,” said David Elkins, president of the American Psychological Association’s society for humanistic psychology and chairman of the committee behind the petition. “But we are concerned about the normal kids and elderly people who are going to be diagnosed with these disorders and treated with psychiatric drugs. We think that’s very, very dangerous.”

“Controversy continues to swell around the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders, better known as DSM-5. A new study suggests the 900-page bible of mental health, scheduled for publication in May 2013, is ripe with financial conflicts of interest.” Katie  Moisse, ABC World News with Dianne Sawyer, March 2012.

QuietMinds makes no allegations.  We simply compiled information regarding the controversy and report it to you.  Like everything with QuietMinds we urge you to research the information and decide for yourself the facts.